drugset / Trial / NCT00776373
Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies
NaSingle-groupOpen-labelTreatment
Summary
Assess the safety, tolerability and efficacy of rapamycin in combination with HiVAC in relapsed and refractory patients with aggressive lymphoid malignancies.
Timeline
- Start
- 2007-01
- Primary completion
- 2008-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | 3 mg | Oral |
| Subject | Sirolimus | Small molecule | 4 mg | Oral |
| Background | Cytarabine | Small molecule | 2000 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 500 mg/m2 | Intravenous |